Shanghai Henlius Biotech Inc represents a set of core values and corporate philosophy. The company aims to prioritize innovation, quality, and patient-centricity in the field of biotechnology. With a strong focus on research and development, Henlius strives to bring affordable and accessible biopharmaceutical products to improve treatment outcomes for patients worldwide. The company values transparency, integrity, and collaboration, believing in the importance of ethical business practices and maintaining trust with stakeholders. Shanghai Henlius Biotech Inc is committed to continuously advancing medical advancements to benefit global healthcare.

Shanghai Henlius Biotech Inc is primarily present in China, with a focus on the domestic market. Being headquartered in Shanghai, the company strategically operates within the country to leverage the vast opportunities and resources available. With its strong presence in China, Shanghai Henlius Biotech Inc aims to serve the growing demand for biotech products and contribute to the advancement of the healthcare industry in the region. As a leading biopharmaceutical company, Shanghai Henlius Biotech Inc continues to expand its footprint and explore potential collaborations and market opportunities both within China and internationally.

Shanghai Henlius Biotech Inc, a leading biopharmaceutical company, has accomplished significant milestones in its journey. The company has successfully developed and commercialized a portfolio of innovative, high-quality therapeutics, particularly in the field of oncology. Henlius became the first company in China to obtain the Marketing Authorization Approval (MAA) for a monoclonal antibody biosimilar, setting a new benchmark in the industry. With a strong focus on research and development, the company has also achieved remarkable progress in advancing its pipeline products. Shanghai Henlius Biotech Inc continues to make strides in improving patient lives through its cutting-edge biotechnological breakthroughs.

Shanghai Henlius Biotech Inc is a renowned biotechnology company based in Shanghai, China. Established in 2010, the company focuses on the research, development, and commercialization of innovative and high-quality biologics. With a strong commitment to healthcare advancement, Shanghai Henlius Biotech Inc has made significant contributions to the biopharmaceutical industry. The company has a diverse portfolio of products that encompass monoclonal antibodies, biosimilars, and next-generation biotherapeutics. Shanghai Henlius Biotech Inc has also established strategic partnerships with domestic and international pharmaceutical companies to enhance its global presence. With its rich history and dedication to improving patients' lives, Shanghai Henlius Biotech Inc has emerged as a leading player in the biotech industry.

Some of the main competitors of Shanghai Henlius Biotech Inc in the market include domestic pharmaceutical companies such as BeiGene Ltd., Hutchison China MediTech Ltd. (Chi-Med), Jiangsu Hengrui Medicine Co., Ltd., and Innovent Biologics Inc. These companies also operate in the biotechnology sector and compete in areas such as research and development of innovative drugs, manufacturing, and commercialization of biopharmaceutical products.

Shanghai Henlius Biotech Inc is primarily active in the biotechnology industry.

The business model of Shanghai Henlius Biotech Inc revolves around the development, manufacturing, and commercialization of innovative biopharmaceutical products. As a leading biotech company in China, Henlius focuses on the research and production of high-quality monoclonal antibodies and biosimilars for the treatment of various diseases, including cancer. By utilizing advanced technology and comprehensive quality control systems, Henlius aims to provide cost-effective and accessible healthcare solutions to patients in need. With its strong R&D capabilities and strategic partnerships, Shanghai Henlius Biotech Inc strives to make significant contributions to the biopharmaceutical industry in both domestic and international markets.

Shanghai Henlius Biotech P/E-luku on 64,44.

Shanghai Henlius Biotech KUV on 1,93.

AlleAktien Laatuscore Shanghai Henlius Biotech on 3/10.

odotettu Shanghai Henlius Biotech liikevaihto on 5,88 miljardia CNY.

odotettu Shanghai Henlius Biotech voitto on 175,87 milj. CNY.

Shanghai Henlius Biotech Inc is a Chinese company that specializes in the development, production, and marketing of innovative biopharmaceuticals. Henlius has built a comprehensive portfolio of biosimilars, novel antibodies, and cell therapies for the treatment of cancer and other serious diseases. One of Henlius's core businesses is the development and production of biosimilars, which can be introduced to the market as cost-effective alternatives to expensive biopharmaceuticals. The company has a team of over 600 employees, including over 200 scientists, who focus on the research and development of biosimilars. The biosimilars are developed and produced in close collaboration with top international partners such as Pfizer, Boehringer Ingelheim, Accord Healthcare, and others. Another important business area for Henlius is the development of novel antibodies for the treatment of cancer. These antibodies specifically target cancer cells and can mobilize the body's immune system to fight cancer. Henlius has several antibody candidates in clinical development and plans to introduce products soon. Henlius is also involved in cell therapy, an emerging field of biotechnology where a patient's own cells are used for the treatment of diseases. Cell therapy can be used for the treatment of cancer, autoimmune diseases, and other conditions. Henlius has several cell therapy products in clinical development and collaborates closely with leading academics and institutions to advance the development of these products. Henlius's business model is based on the combination of research, development, and production of novel biopharmaceuticals. Henlius has built a comprehensive platform for the development of biosimilars, novel antibodies, and cell therapy products, supported by experienced scientists and a dedicated leadership team. Henlius's products have the potential to improve the lives of millions of patients worldwide and make the company a key player in the biopharmaceutical market. Overall, Henlius has developed a wide range of products and services to meet the needs of patients and the market. The company relies on collaboration with leading partners and institutions to accelerate the development and production of biopharmaceuticals. Henlius has ambitious plans for the future and is likely to play a significant role in the development of biosimilars, novel antibodies, and cell therapies.

Shanghai Henlius Biotech maksaa osinkoa 0 CNY, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Shanghai Henlius Biotech:lle tai yhtiö ei maksa osinkoa.

Shanghai Henlius Biotech:n ISIN on CNE100003N76.

Shanghai Henlius Biotech:n tunnus on 2696.HK.

Viimeisen 12 kuukauden aikana Shanghai Henlius Biotech maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Shanghai Henlius Biotech maksanee ennusteiden mukaan 0 CNY osingon.

Shanghai Henlius Biotech:n tämänhetkinen osinkotuotto on .

Shanghai Henlius Biotech maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Shanghai Henlius Biotech maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 CNY suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Shanghai Henlius Biotech kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Shanghai Henlius Biotech osingon 31.7.2024, jonka suuruus on 0 CNY, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 31.7.2024.

Viimeisin osinko maksettiin 31.7.2024.

Vuonna 2023 Shanghai Henlius Biotech maksoi 0 CNY osinkoina.

Shanghai Henlius Biotech:n osingot maksetaan CNYssa.